Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 6/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | CBFB | Q13951 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968392 | 0.89 | NPC1 (0.39) | HTTFGFR1LMNASMN1; SMN2 | |
| SCHEMBL3081829 | 0.86 | CYP11B1 (0.39) | ACSS2CYP11B1CYP11B2TNFASAH1 | |
| SCHEMBL1876428 | 0.81 | FGFR1 (0.45) | CYP11B1CYP11B2HTTFGFR1MAPK1 | |
| SCHEMBL29795166 | 0.79 | HTT (0.35) | CYP11B1CYP11B2TNFHTTFGFR1 | |
| SCHEMBL3856673 | 0.78 | FGFR1 (0.45) | ACSS2CYP11B1CYP11B2HTTFGFR1 | |
| SCHEMBL29447536 | 0.78 | NPC1 (0.39) | CYP11B1CYP11B2HTTFGFR1LMNA | |
| SCHEMBL3037362 | 0.78 | NPC1 (0.39) | CYP11B1CYP11B2HTTFGFR1LMNA | |
| SCHEMBL2794301 | 0.76 | HTT (0.48) | CYP11B1CYP11B2TNFASAH1HTT | |
| SCHEMBL17940703 | 0.75 | FGFR1 (0.60) | HTTFGFR1MAPK1 | |
| SCHEMBL9049120 | 0.74 | MAPT (0.38) | CYP11B1CYP11B2TNFHTTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1445249-B1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | ACSS2 811/4885CYP11B1 2042/4885CYP11B2 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.